Almirall has hosted the fourth edition of ImmunoSkin, its annual scientific forum focused on advancing the understanding and treatment of inflammatory skin conditions.

Held in Madrid from 8 to 9 November, the meeting brought together leading dermatology experts to discuss the latest developments in disease mechanisms, clinical management, and innovation in immune-mediated skin conditions including atopic dermatitis, psoriasis, hidradenitis suppurativa and alopecia areata.

Chaired by Christian Vestergaard, professor and dermatologist at Aarhus University Hospital in Denmark, the two-day event combined scientific presentations, panel discussions and workshops. Sessions explored four main areas identified as key to treatment success: advances in skin immunology, clinical perspectives, patient experiences, and current and emerging therapeutic innovation.

Workshops highlighted new data on treatment options targeting IL-13 for atopic dermatitis and IL-23 for psoriasis, reflecting growing understanding of how modulation of immune pathways can improve clinical outcomes. Further sessions examined research into T-cell biology and the future potential of immune-therapeutic approaches to achieve lasting disease modification in chronic skin conditions.

A focus on holistic care addressed the psychological and social impact of skin disease. Presentations discussed the use of the World Health Organization Well-Being Index (WHO-5) to measure mental health outcomes in dermatology, showing that chronic skin conditions can significantly affect emotional well-being and relationships. Speakers also noted how effective treatment can deliver improvements beyond physical symptom relief, in line with the WHO’s 2025 resolution recognising skin diseases as a global public health priority.

Christian Vestergaard said: “ImmunoSkin is a unique opportunity to focus on advancing our understanding of inflammatory skin diseases and their treatments. The focus on collaboration and scientific exchange, paired with sharing foundational patient insights on inflammatory skin diseases and treatment outcomes is immensely powerful to further drive treatment success and patient outcomes for some of the most debilitating dermatological conditions.”

Volker Koscielny, chief medical officer at Almirall, added: “Advancing science and treatment success for skin diseases is based on collaboration and expert exchange – this is what the multi-faceted and meaningful exchange at ImmunoSkin facilitates, bringing together clinicians and international thought leaders in dermatology. We are proud to contribute in improving treatment outcomes for patients suffering from skin diseases – from increasing understanding at the molecular level all the way to psychological well-being.”

Now in its fourth year, ImmunoSkin has become an established forum for collaboration in dermatology, fostering dialogue between clinicians, researchers and industry experts to translate scientific progress into improved patient care.